Endocrine Abstracts

Octreotide LAR (SMS-LAR) is available in 10, 20 and 30 mg dosing. The relation-ship between SMS-LAR starting dose and GH, IGF-I and symptoms was exam-ined. The Observational Acromegaly Study on Impact of Sandostatin LAR (OASIS) collects data on GH, IGF-I, symptoms, safety and tolerability in recently diagnosed acromegalic patients. Data are collected under normal practice conditions over 12 mos. Eight hundred and sixty patients from 138 centers in 23 countries are enrolled; 35...

Corticotrope cells give arise to utmost aggressive and to very rare pituitary neoplasias, including pituitary carcinomas, Crooke’s cell adenomas (CCA), clinically non-functioning silent corticotrope adenomas (SCA) and the Cushing-provoking pituitary adenomas (CD). The molecular etiopathogenesis of these tumors are still poorly understood. Therefore, we carried out whole exome sequencing to better understand the full genomic landscape single nucleotide variants and copy nu...

The tumor immune microenvironment is essential, it could influence a favorable or negative response against the tumor cells, and it has been related to therapy response and prognostic factors. Tumor infiltrating lymphocytes (TILs) plays an important role in the development, progression, and tumor control, thus presence of TILs could be related to disease-specific traits. The aim of the present work is to evaluate the expression of immune-related genes in forty-two pituitary ad...

The tumor microenvironment (TME) includes diverse cellular components such as mesenchymal stem cells (MSC) and immune cells. MSC are a subset of heterogeneous cell populations characterized by the expression of CD105, CD73, and CD90 that can differentiate into chondrocytes, osteoblasts, and adipocytes in vitro. They are known to have immunomodulatory capabilities. Our aim was to isolate and characterize the immunomodulatory capabilities of MSC from pituitary tumors (P...

Background: There is significant interest in how the use of different treatment regimens (e.g. surgery, medical therapy) impacts the clinical course of Acromegaly. This study has been designed to better understand clinical decision making in the context of various treatment options.Methods: OASIS is an international, observational study in recently diagnosed acromegalic patients. Ethical committee approval was obtained where applicable. Observations incl...

Pituitary adenomas (PA) are primarily benign lesions with monoclonal origins from the adenohypophyseal cells and represent 10-15% of all intracranial tumors. Tumors derived from POU1F1 cell lineage are GH-, TSH-, and PRL-secreting tumors that cause important syndromes such as acromegaly, hyperthyroidism, and sexual dysfunction, respectively. Surgical resection is the first line of treatment; the secondary treatment is pharmacological; despite having targets pharmacological in ...

Pituitary tumors (PT) represent 20% of all intracranial neoplasms. Some behave aggressively, growing rapidly and invading surrounding tissues, with high recurrence rates and are frequently resistant to conventional therapies. We performed exome and transcriptome sequencing, as well as methylation profiling of primary and recurrent PT of the same patient. The cohort consisted of patients with GH- and gonadotropin-producing PT and a patient with an ACTH carcinom...

Introduction: Non-syndromic pituitary gigantism can result from AIP mutations and the recently identified Xq26.3 microduplications causing X-LAG.Patients and methods: DNA samples and clinical data were collected from 151 patients with pituitary gigantism. All samples were tested for AIP mutations; AIP mutation negative cases (AIPneg) were screened for Xq26.3 microduplications.Results: Xq26.3 micr...

Background: A founder mutated AIP allele, R304* was previously identified in several Irish familial isolated pituitary adenoma (FIPA) pedigrees from a small region within Mid Ulster, Northern Ireland, but the allele’s general population impact remains unknown.Aims: To estimate R304* prevalence in the general population and pituitary adenoma (PA) patients and to calculate the allele’s time to most recent common ancestor (tMRCA).<p c...